Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342360 | 0.96 | TDP1 (0.35) | TDP1KDM5AKDM4C | |
| SCHEMBL21215101 | 0.85 | CA12 (0.43) | BLMPMP22HSD17B10TDP1KDM4E | |
| SCHEMBL20206397 | 0.82 | CES2 (0.42) | KDM5AKDM4C | |
| SCHEMBL8390805 | 0.81 | CA12 (0.41) | TDP1KDM4ECA12CA1CA2 | |
| SCHEMBL19396417 | 0.80 | CHRM2 (0.43) | BLMPMP22TDP1KDM4ECA12 | |
| SCHEMBL22005808 | 0.79 | BLM (0.32) | BLMPMP22HSD17B10TDP1KDM4E | |
| SCHEMBL21026058 | 0.79 | ALDH1A1 (0.35) | BLMPMP22HSD17B10TDP1 | |
| SCHEMBL20206300 | 0.79 | BLM (0.32) | BLMPMP22HSD17B10KDM4E | |
| SCHEMBL21935307 | 0.78 | CES2 (0.36) | TDP1KDM4ECA12CA1CA2 | |
| SCHEMBL30743340 | 0.77 | KDM5A (0.35) | KDM4EKDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352351-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352351-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ESRRA, MDM2 | BLM 3995/4885PMP22 4866/4885HSD17B10 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.